• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在正常受试者中,静脉注射维拉帕米并预先静脉注射氯化钙后,对其药代动力学和心电图效应的评估。

Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.

作者信息

Schoen M D, Parker R B, Hoon T J, Hariman R J, Bauman J L, Beckman K J

机构信息

Department of Pharmacy Practice, University of Illinois, Chicago 60612.

出版信息

Am J Cardiol. 1991 Feb 1;67(4):300-4. doi: 10.1016/0002-9149(91)90563-z.

DOI:10.1016/0002-9149(91)90563-z
PMID:1990794
Abstract

To evaluate the effects of calcium pretreatment on the disposition and electrocardiographic effects of verapamil, 8 healthy male volunteers received treatment in each of 3 phases in a randomized, double-blind, crossover manner. Phase I denoted 10 ml of 0.9% intravenous sodium chloride followed by 10 mg of intravenous verapamil; phase II denoted 10 ml of 10% intravenous calcium chloride followed by 4 ml of 0.9% intravenous sodium chloride; and phase III denoted 10 ml of 10% intravenous calcium chloride followed by 10 mg of intravenous verapamil. Blood samples for the determination of verapamil concentrations were drawn at 5, 10, 15, 20, 30, 45, 60 and 90 minutes, and at 2, 4, 6, 10 and 24 hours. Blood pressure, heart rate and PR intervals were also measured at these times. Pretreatment of verapamil with intravenous calcium did not alter the disposition of intravenous verapamil. Blood pressure was not significantly altered in any treatment phase, although calcium tended to increase mean arterial pressure and verapamil abolished this effect. Calcium had no significant affect on verapamil-induced PR prolongation (maximum percent change in PR interval: phase I = 19 +/- 11%, phase III = 18 +/- 7%; time to maximal prolongation: phase I = 0.38 +/- 0.21 hours, phase III = 0.37 +/- 0.26 hours; and area under the percent change in PR vs time curve: phase I = 15.5 +/- 10, phase III = 21 +/- 9). Verapamil caused a reflex increase in heart rate of similar magnitude in both phases I and III (24 +/- 10% and 21 +/- 7%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为评估钙预处理对维拉帕米的处置及心电图效应的影响,8名健康男性志愿者按随机、双盲、交叉方式在3个阶段分别接受治疗。第一阶段为静脉注射10ml 0.9%氯化钠溶液,随后静脉注射10mg维拉帕米;第二阶段为静脉注射10ml 10%氯化钙溶液,随后静脉注射4ml 0.9%氯化钠溶液;第三阶段为静脉注射10ml 10%氯化钙溶液,随后静脉注射10mg维拉帕米。在5、10、15、20、30、45、60和90分钟以及2、4、6、10和24小时采集血样以测定维拉帕米浓度。在这些时间点还测量血压、心率和PR间期。静脉注射钙预处理维拉帕米未改变静脉注射维拉帕米的处置。尽管钙倾向于升高平均动脉压,且维拉帕米消除了这种效应,但在任何治疗阶段血压均未显著改变。钙对维拉帕米引起的PR间期延长无显著影响(PR间期最大变化百分比:第一阶段=19±11%,第三阶段=18±7%;达到最大延长时间:第一阶段=0.38±0.21小时,第三阶段=0.37±0.26小时;PR间期变化百分比与时间曲线下面积:第一阶段=15.5±10,第三阶段=21±9)。在第一阶段和第三阶段,维拉帕米引起的心率反射性增加幅度相似(分别为24±10%和21±7%)。(摘要截短于250字)

相似文献

1
Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.在正常受试者中,静脉注射维拉帕米并预先静脉注射氯化钙后,对其药代动力学和心电图效应的评估。
Am J Cardiol. 1991 Feb 1;67(4):300-4. doi: 10.1016/0002-9149(91)90563-z.
2
R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.R-维拉帕米:药代动力学及其对PR间期、血压和心率的影响
Br J Clin Pharmacol. 1993 Aug;36(2):93-8. doi: 10.1111/j.1365-2125.1993.tb04202.x.
3
Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.维拉帕米与普萘洛尔在正常受试者中潜在药效学和药代动力学相互作用的评估。
Br J Clin Pharmacol. 1991 Mar;31(3):323-32. doi: 10.1111/j.1365-2125.1991.tb05536.x.
4
Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit.大剂量静脉持续输注维拉帕米的药代动力学和药效学效应:重症监护病房的临床经验
Crit Care Med. 1999 Feb;27(2):332-9. doi: 10.1097/00003246-199902000-00040.
5
Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment.静脉注射维拉帕米治疗伴或不伴钙预处理的多源性房性心动过速。
Ann Intern Med. 1987 Nov;107(5):623-8. doi: 10.7326/0003-4819-107-5-623.
6
Verapamil pharmacodynamics and disposition in obese hypertensive patients.维拉帕米在肥胖高血压患者中的药效学及处置情况
J Cardiovasc Pharmacol. 1988 Feb;11(2):209-15.
7
Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline.在使用阿托品、钙剂和生理盐水复苏的严重维拉帕米中毒动物模型中静脉注射脂肪乳剂的血流动力学效应。
Acad Emerg Med. 2007 Feb;14(2):105-11. doi: 10.1197/j.aem.2006.10.094.
8
Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects.食物对正常受试者中维拉帕米缓释制剂药代动力学及心电图效应的影响。
Am J Cardiol. 1992 Oct 15;70(11):1072-6. doi: 10.1016/0002-9149(92)90363-4.
9
Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.老年患者单次静脉注射和口服维拉帕米后的药物处置及心血管效应
Cardiovasc Drugs Ther. 1989 Jun;3(3):417-25. doi: 10.1007/BF01858113.
10
Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil.舌下含服与静脉注射维拉帕米的药代动力学及心电图效应比较。
Pharmacotherapy. 1992;12(1):33-9.